Linerixibat for severe itching from primary biliary cholangitis
Part of Digestive system, Skin clinical trials.
This trial tests an investigational medicine called linerixibat for people with primary biliary cholangitis (PBC) who have severe itching that hasn't responded to other treatments and who are at risk of serious complications from the itching. It aims to help reduce this itching and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have been diagnosed with primary biliary cholangitis (PBC).
- You have severe itching caused by PBC that has not improved with other available treatments, or those treatments were not right for you.
- You are at high risk of a serious health event because of the itching, as determined by your doctor.
- If you are a woman who could become pregnant, you must not be pregnant or breastfeeding and must use an acceptable birth control method during treatment and for at least 4 weeks after the last dose.
- You do not have advanced liver disease (like cirrhosis with certain severe complications) or current liver decompensation such as bleeding or confusion.
- You are not currently taking obeticholic acid or another IBAT inhibitor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study continues to test an experimental medicine (linerixibat) for itching caused by primary biliary cholangitis (PBC). It's for people who have already been in a prior study of this medicine and may help keep itching under control.
This trial tests an experimental drug called TH104 to see if it can reduce itching in people with primary biliary cholangitis. The study will help find out if TH104 is safe and effective for this symptom.
This Phase 3 study tests whether dupilumab injections can reduce severe itching that has no clear cause. It also checks how safe the medicine is over the study period.
This study looks at itching caused by drug-induced liver injury. Researchers want to understand who gets itchy and how bad it is, which could help improve care for people with this condition.
This trial tests whether upadacitinib, a drug that calms the immune system, can help people with autoimmune liver disease and severe itching from atopic dermatitis (eczema). It aims to reduce itching and improve liver health.
This study tests a medication called maralixibat for treating intrahepatic cholestasis of pregnancy (ICP), a liver condition that causes severe itching and can affect the baby. The goal is to see if it safely lowers bile acids and improves outcomes for you and your baby.
Hear when a new Pruritus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.